SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases

SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases

Abstract Background Stereotactic radiosurgery (SRS) is a frequently chosen treatment for patients with brain metastases and the number of long-term survivors is increasing. Brain necrosis (e.g. radionecrosis) is the most important long-term side effect of the treatment. Retrospective studies show a...

Full description

Bibliographic Details
Main Authors: J. A. Crouzen, A. L. Petoukhova, M. L. D. Broekman, M. Fiocco, U. J. Fisscher, J. H. Franssen, C. G. M. Gadellaa-van Hooijdonk, M. Kerkhof, M. Kiderlen, M. E. Mast, C. M. van Rij, R. Nandoe Tewarie, M. A. E. van de Sande, P. P. G. van der Toorn, R. Vlasman, M. J. Vos, N. C. M. G. van der Voort van Zyp, R. G. J. Wiggenraad, L. M. Wiltink, J. D. Zindler
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
Stereotactic radiosurgery (SRS)
Fractionated stereotactic radiosurgery (fSRS)
Brain metastases
Radionecrosis
Brain necrosis
Hypofractionation
Online Access:https://doi.org/10.1186/s12885-023-10761-1

Internet

https://doi.org/10.1186/s12885-023-10761-1

Similar Items